Rob J. Morgan, III, M.D., Ph.D.

Closed for Enrollment

• Cross-Sectional Case-Controlled Investigation of Subclinical Atherosclerotic Disease and Subclinical Inflammation in Patients with Mood Disorders versus Healthy and non-Mood Disorder Controls: A Pilot and Feasibility Study Rochester, Minn.

  The overall goal is to better understand the underlying pathophysiology of mood disorders and bipolar disorders in particular. We aim to investigate whether the subclinical atherosclerotic and inflammatory markers differ between patients with bipolar disorder, major depressive disorder, and psychiatric non-mood disorders and healthy subjects.

• State-Specific Serum CNS Autoantibody and Inflammatory Marker Investigation in Bipolar and Schizoaffective Disorder Rochester, Minn.

  The purpose of this study is to find out if some patients with mood symptoms have antibodies (part of the immune system) that affect the brain, and could possibly play a role in the development of mood symptoms. We also want to find out if these immune markers change once your mood normalizes.

• State-Specific Serum CNS Autoantibody and Inflammatory Marker Investigation in Catatonia Rochester, Minn.

  The overall objective of this study is to compare seroprevalence rates, titers of central nervous system (CNS) autoantibodies, and inflammatory markers in catatonic patients.